Diverticulitis Clinical Trial
Official title:
Effect of Gum Arabic on Gastrointestinal Transit and Permeability
Verified date | July 2023 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to determine the effect of gum arabic on gut bacteria and GI function.
Status | Completed |
Enrollment | 27 |
Est. completion date | March 1, 2021 |
Est. primary completion date | March 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Recent diagnosis of diverticulitis (within 24 months) and at least 4 weeks post antibiotic use 2. Age 18-80 Exclusion Criteria: 1. Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy) 2. Known diagnosis of inflammatory bowel disease (Crohn's or ulcerative colitis), microscopic colitis, celiac disease, or other inflammatory condition other than diverticulitis 3. Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability) 4. Use of NSAIDs or aspirin within the week prior to Visit 2 and Visit 5 (permeability and transit testing visit since NSAIDs affect intestinal permeability) 5. Use of osmotic laxatives one week prior to Visit 2 and for the duration of the study 6. Use of oral corticosteroids within the previous 6 weeks and for the duration of the study 7. Ingestion of artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days before and during the permeability testing days, e.g. foods to be avoided are sugarless gums or mints and diet beverages 8. Antibiotic use within 4 weeks of completion of the initial stool kit and/or Visit 2 testing appointment and for the remainder of the study (they can complete the stool kit and Visit 2 after a 4-week washout period) 9. Bowel preparation for colonoscopy less than one week prior to the completion of the first stool kit and Visit 2 and during the remainder of the study 10. Pregnancy or plan to become pregnant within the study timeframe 11. Vulnerable adults 12. Egg allergy or resistant to ingesting eggs 13. Diagnosis of diabetes 14. Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Colonic Transit time | The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. Units: units on a scale | Change is being assessed between baseline and 6 weeks | |
Secondary | Intestinal Permeability | To determine intestinal permeability, urine will be collected for 24 hours after drinking a sugar solution. The 0- to 2-hour urine most closely reflects small intestinal permeability and the 8- to 24-hour urine reflects colonic permeability. HPLC-tandem mass spectrometry will be used for detection of the sugars. | Change is being assessed between baseline and 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02246361 -
Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication
|
Phase 4 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01081054 -
Hospitalization or Ambulatory Treatment of Acute Diverticulitis
|
Phase 4 | |
Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
Completed |
NCT03337984 -
Damage Control Surgery in the Treatment of Complicated Diverticulitis
|
||
Recruiting |
NCT06210724 -
FIT in Diverticulitis
|
||
Completed |
NCT01986686 -
Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis
|
N/A | |
Completed |
NCT01477190 -
Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program
|
Phase 1/Phase 2 | |
Completed |
NCT01056913 -
NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
|
Phase 4 | |
Completed |
NCT00468455 -
Post-Op Quality of Life After Colorectal Surgery
|
N/A | |
Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
Enrolling by invitation |
NCT03700593 -
Feasibility and Safety of Single Port Robot in Colorectal Procedures
|
||
Recruiting |
NCT04095663 -
Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
|
N/A | |
Completed |
NCT00545740 -
Prevention of Recurrence of Diverticulitis
|
Phase 3 | |
Recruiting |
NCT01837342 -
Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
|
N/A | |
Completed |
NCT01727388 -
Informativeness to Digital Rectal Examination
|
Phase 3 | |
Completed |
NCT00554099 -
Asacol Acute Diverticulitis(DIVA)Study
|
Phase 2 | |
Completed |
NCT04173182 -
Confocal Laser Endomicrospy in Colonic Diverticular Disease
|
||
Completed |
NCT01560377 -
Perfusion Assessment in Laparoscopic Left Anterior Resection
|
Phase 1 |